Compare Stocks: CPIX, ASMB, SPRY, and AVIR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASMB Assembly Biosciences	$22.54 -1.9%	$29.09	$21.80 ▼ $39.71	$458.94M	1.15	376,115 shs	367,967 shs
AVIR Atea Pharmaceuticals	$5.13 +0.6%	$5.23	$2.81 ▼ $6.45	$411.45M	0.39	295,226 shs	253,264 shs
CPIX Cumberland Pharmaceuticals	$7.39 -1.6%	$7.40	$1.85 ▼ $9.28	$110.72M	0.06	37,973 shs	22,629 shs
SPRY ARS Pharmaceuticals	$4.07 -1.2%	$5.26	$3.98 ▼ $13.15	$404.75M	0.85	1.40 million shs	1.83 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASMB Assembly Biosciences	0.00%	-4.77%	-37.61%	-18.75%	-8.41%
AVIR Atea Pharmaceuticals	0.00%	-0.77%	-11.86%	+3.01%	+78.13%
CPIX Cumberland Pharmaceuticals	0.00%	-2.89%	+9.48%	+16.01%	+136.86%
SPRY ARS Pharmaceuticals	0.00%	-0.25%	-28.22%	-52.45%	-59.66%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASMB Assembly Biosciences	$22.54 -1.9%	$29.09	$21.80 ▼ $39.71	$458.94M	1.15	376,115 shs	367,967 shs
AVIR Atea Pharmaceuticals	$5.13 +0.6%	$5.23	$2.81 ▼ $6.45	$411.45M	0.39	295,226 shs	253,264 shs
CPIX Cumberland Pharmaceuticals	$7.39 -1.6%	$7.40	$1.85 ▼ $9.28	$110.72M	0.06	37,973 shs	22,629 shs
SPRY ARS Pharmaceuticals	$4.07 -1.2%	$5.26	$3.98 ▼ $13.15	$404.75M	0.85	1.40 million shs	1.83 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASMB Assembly Biosciences	0.00%	-4.77%	-37.61%	-18.75%	-8.41%
AVIR Atea Pharmaceuticals	0.00%	-0.77%	-11.86%	+3.01%	+78.13%
CPIX Cumberland Pharmaceuticals	0.00%	-2.89%	+9.48%	+16.01%	+136.86%
SPRY ARS Pharmaceuticals	0.00%	-0.25%	-28.22%	-52.45%	-59.66%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASMB Assembly Biosciences	2.83	Moderate Buy	$47.50	110.74% Upside
AVIR Atea Pharmaceuticals	2.33	Hold	$7.00	36.45% Upside
CPIX Cumberland Pharmaceuticals	1.00	Sell	N/A	N/A
SPRY ARS Pharmaceuticals	2.50	Moderate Buy	$25.00	514.25% Upside

Current Analyst Ratings Breakdown

Latest CPIX, ASMB, SPRY, and AVIR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/21/2026	CPIX Cumberland Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/8/2026	SPRY ARS Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$15.00
9/1/2026	ASMB Assembly Biosciences	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$53.00
9/1/2026	ASMB Assembly Biosciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$52.00
9/1/2026	ASMB Assembly Biosciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$52.00
9/1/2026	ASMB Assembly Biosciences	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$53.00 ➝ $45.00
8/20/2026	ASMB Assembly Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/18/2026	ASMB Assembly Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
8/17/2026	SPRY ARS Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	AVIR Atea Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$6.00 ➝ $7.00
7/17/2026	ASMB Assembly Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASMB Assembly Biosciences	$72.30M	6.35	N/A	N/A	$13.04 per share	1.73
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	$3.53 per share	N/A
CPIX Cumberland Pharmaceuticals	$44.52M	2.49	$0.37 per share	20.15	$1.64 per share	4.51
SPRY ARS Pharmaceuticals	$84.28M	4.80	N/A	N/A	$1.16 per share	3.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASMB Assembly Biosciences	-$6.12M	$1.02	22.10	450.80	N/A	-0.06%	-0.02%	-0.02%	11/9/2026 (Estimated)
AVIR Atea Pharmaceuticals	-$158.35M	-$2.08	N/A	N/A	N/A	N/A	-64.25%	-57.12%	11/11/2026 (Estimated)
CPIX Cumberland Pharmaceuticals	-$2.84M	-$0.71	N/A	N/A	N/A	-34.40%	-28.81%	-9.25%	11/3/2026 (Estimated)
SPRY ARS Pharmaceuticals	-$171.30M	-$2.18	N/A	N/A	N/A	-184.24%	-256.67%	-69.63%	11/9/2026 (Estimated)

Latest CPIX, ASMB, SPRY, and AVIR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ASMB Assembly Biosciences	-$0.7242	-$0.20	+$0.5242	-$0.20	$8.60 million	$13.37 million
8/13/2026	Q2 2026	SPRY ARS Pharmaceuticals	-$0.4777	-$0.63	-$0.1523	-$0.63	$31.32 million	$33.66 million
8/12/2026	Q2 2026	AVIR Atea Pharmaceuticals	-$0.5550	-$0.41	+$0.1450	-$0.41	$33.03 million	N/A
8/4/2026	Q2 2026	CPIX Cumberland Pharmaceuticals	-$0.13	-$0.20	-$0.07	-$0.29	$8.50 million	$0.17 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASMB Assembly Biosciences	N/A	N/A	N/A	N/A	N/A
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CPIX Cumberland Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest CPIX, ASMB, SPRY, and AVIR Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/13/2026	CPIX Cumberland Pharmaceuticals		$1.50			7/23/2026	7/31/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASMB Assembly Biosciences	N/A	13.99	13.99
AVIR Atea Pharmaceuticals	N/A	8.13	8.13
CPIX Cumberland Pharmaceuticals	N/A	0.96	0.96
SPRY ARS Pharmaceuticals	13.72	3.48	3.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASMB Assembly Biosciences	19.92%
AVIR Atea Pharmaceuticals	86.67%
CPIX Cumberland Pharmaceuticals	15.51%
SPRY ARS Pharmaceuticals	68.16%

Insider Ownership

Company	Insider Ownership
ASMB Assembly Biosciences	3.50%
AVIR Atea Pharmaceuticals	21.60%
CPIX Cumberland Pharmaceuticals	42.07%
SPRY ARS Pharmaceuticals	33.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASMB Assembly Biosciences	73	20.36 million	19.65 million	Optionable
AVIR Atea Pharmaceuticals	55	80.21 million	62.88 million	Optionable
CPIX Cumberland Pharmaceuticals	93	14.98 million	8.68 million	Optionable
SPRY ARS Pharmaceuticals	200	99.45 million	65.83 million	Optionable

CPIX, ASMB, SPRY, and AVIR Headlines

Recent News About These Companies

ARS PHARMACEUTICALS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action - SPRY

9 minutes ago | newsfilecorp.comN

SPRY INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

October 4 at 8:53 AM | newsfilecorp.comN

ARS Pharmaceuticals (NASDAQ:SPRY) & Sunshine Biopharma (NASDAQ:SBFM) Critical Survey

October 4 at 5:14 AM | americanbankingnews.com

SPRY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

October 3 at 8:41 AM | newsfilecorp.comN

ARS PHARMACEUTICALS DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages ARS Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 5 Deadline in Securities Class Action - SPRY

October 3 at 7:24 AM | newsfilecorp.comN

ARS Pharmaceuticals Officer Eric Karas Files Form 144 to Sell 100,000 Shares on NASDAQ

October 2 at 7:54 PM | kalkinemedia.comK

ARS Pharmaceuticals Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit

October 2 at 6:01 PM | prnewswire.com

ARS PHARMACEUTICALS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRY

October 2 at 2:57 PM | globenewswire.com

ARS PHARMACEUTICALS DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals Investors to Contact the Firm Before October 5th Seeking Lead Plaintiff Role

October 2 at 2:43 PM | globenewswire.com

Kaplan Fox Class Action Reminder: ARS Pharmaceuticals Inc. (SPRY) Lead Plaintiff Deadline is October 5, 2026

October 1 at 4:30 PM | newsfilecorp.comN

Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm

October 1 at 12:00 PM | globenewswire.com

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

October 1 at 10:26 AM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY

October 1 at 10:00 AM | prnewswire.com

SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

October 1 at 9:53 AM | prnewswire.com

Critical Survey: ARS Pharmaceuticals (NASDAQ:SPRY) and Nutriband (NASDAQ:NTRB)

October 1 at 6:15 AM | americanbankingnews.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Now Rated "Moderate Buy" by Sell-Side Analysts

October 1 at 6:14 AM | americanbankingnews.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Has Consensus Price Target of $25.00

October 1 at 6:13 AM | marketbeat.com

ARS PHARMACEUTICALS DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages ARS Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 5 Deadline in Securities Class Action - SPRY

September 30, 2026 | newsfilecorp.comN

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY

September 30, 2026 | prnewswire.com

ARS Pharmaceuticals, Inc. (SPRY)

September 30, 2026 | finance.yahoo.com

Bank of America Corp DE Makes New Investment in ARS Pharmaceuticals, Inc. $SPRY

September 30, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPIX, ASMB, SPRY, and AVIR Company Descriptions

Assembly Biosciences NASDAQ:ASMB

$22.54 -0.44 (-1.91%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$22.76 +0.23 (+1.00%)

As of 10/2/2026 07:30 PM Eastern

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Atea Pharmaceuticals NASDAQ:AVIR

$5.13 +0.03 (+0.59%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$5.25 +0.12 (+2.34%)

As of 10/2/2026 07:30 PM Eastern

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Cumberland Pharmaceuticals NASDAQ:CPIX

$7.39 -0.12 (-1.60%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$7.42 +0.03 (+0.34%)

As of 10/2/2026 04:10 PM Eastern

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

ARS Pharmaceuticals NASDAQ:SPRY

$4.07 -0.05 (-1.21%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$4.14 +0.07 (+1.72%)

As of 10/2/2026 07:44 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CPIX, ASMB, SPRY, and AVIR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CPIX, ASMB, SPRY, and AVIR Earnings

Compare Dividends

Latest CPIX, ASMB, SPRY, and AVIR Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CPIX, ASMB, SPRY, and AVIR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPIX, ASMB, SPRY, and AVIR Company Descriptions

Assembly Biosciences NASDAQ:ASMB

Atea Pharmaceuticals NASDAQ:AVIR

Cumberland Pharmaceuticals NASDAQ:CPIX

ARS Pharmaceuticals NASDAQ:SPRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CPIX, ASMB, SPRY, and AVIR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CPIX, ASMB, SPRY, and AVIR Earnings

Compare Dividends

Latest CPIX, ASMB, SPRY, and AVIR Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CPIX, ASMB, SPRY, and AVIR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPIX, ASMB, SPRY, and AVIR Company Descriptions

Assembly Biosciences NASDAQ:ASMB

Atea Pharmaceuticals NASDAQ:AVIR

Cumberland Pharmaceuticals NASDAQ:CPIX

ARS Pharmaceuticals NASDAQ:SPRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools